Pacira | PCRX - Betriebsaufwand

Aktienkurs
22.35
Täglich Wechseln
0.04 0.18%
Monatlich
-10.24%
Jährlich
-16.45%
Q2 Prognose
22.18




Betriebsaufwand Veränderung Datum
Assertio Holdings USD 105.8M 12.5M 2025-09
Astellas Pharma JPY 489.36B 52.69B 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Cara Therapeutics USD 5.94M 983K 2025-09
Coherus Biosciences USD 51.83M 2.48M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
J&J USD 17.44B 1.53B 2026-03
Ligand Pharmaceuticals USD 34.35M 5.27M 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Novo Nordisk DKK 37.21B 9.56B 2026-03
Omeros USD 59.16M 20.13M 2024-06
Pacira USD 172.75M 20.93M 2026-03
Perrigo USD 935.6M 89.6M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Supernus Pharmaceuticals USD 1.08B 879.06M 2026-03
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03
Xeris Pharmaceuticals USD 69.03M 1.38M 2025-12
Xoma USD 22.84M 1.67M 2024-09
Zoetis USD 3.23B 1.68B 2026-03